- Home
- RLX vs TARS Comparison
RLX vs TARS Comparison
Compare RLX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLX | TARS |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RLX | TARS |
|---|---|---|
| Price | $2.02 | $67.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.5M | 923.1K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $55.89 | $56.43 |
| Revenue Next Year | $15.07 | $30.19 |
| P/E Ratio | $28.09 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $1.76 | $48.20 |
| 52 Week High | $2.68 | $85.25 |
Technical Indicators
Market Signals| Indicator | RLX | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 64.64 |
| Support Level | $1.91 | $65.93 |
| Resistance Level | $2.09 | $73.45 |
| Average True Range (ATR) | 0.06 | 3.13 |
| MACD | -0.00 | 1.01 |
| Stochastic Oscillator | 64.71 | 94.61 |
Price Performance
Historical ComparisonAbout RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.